AstraZeneca shares recover as senior sources deny merger talks with Bristol Myers Squibb
AstraZeneca shares climbed 2.5%, adding 296p to reach 12,036p, after senior sources dismissed speculation about merger discussions with US pharmaceutical giant Bristol Myers Squibb. The recovery came following Monday's steep decline that erased £17 billion from the company's market capitalisation.
Reuters cited a senior source stating categorically: "There is no deal between AstraZeneca and BMS. There never was a deal to be done, and there are no discussions between the companies." A second source confirmed no active talks were underway between the firms.
Bristol Myers Squibb shares fell 3% on Wall Street in response to the denials.
Market turbulence following merger speculation
The Cambridge-based pharmaceutical company, which employs approximately 96,100 people and ranks among Britain's most valuable publicly listed firms, saw its shares plunge 8.96% on Monday as merger rumours circulated. The sell-off reflected investor and analyst scepticism about the strategic rationale behind such a deal.
Had the merger materialised, it would have created pharmaceutical industry history. The combined entity would have been valued at approximately $400 billion, dwarfing previous mega-deals including Bristol Myers Squibb's $74 billion acquisition of Celgene in 2019 and AbbVie's $63 billion purchase of Allergan in 2020.
Coming into Monday's trading, AstraZeneca commanded a market capitalisation of approximately $264 billion, while Bristol Myers Squibb was valued at roughly $133 billion.
Analyst doubts over deal logic
Market analysts questioned why AstraZeneca would pursue such a transaction given its strong performance trajectory. The company is targeting $80 billion in total sales by 2030, up from $58.7 billion in 2025, and has seen consistent market value growth under chief executive Pascal Soriot, who has led the business since 2012.
Jefferies analysts captured the prevailing sentiment, stating that AstraZeneca is "one company that doesn't need financial engineering" given its robust growth profile and innovation pipeline. The firm's oncology franchise alone generated around $25 billion in 2025, representing nearly half its total revenue.
Regulatory obstacles loom
Any potential merger would likely have faced substantial antitrust scrutiny. Both companies maintain significant overlapping portfolios in oncology, which would have created the broadest cancer drug portfolio in the industry and drawn intensive regulatory examination.
Geographic revenue patterns also differ markedly between the two firms. Bristol Myers Squibb derives approximately 69% of its revenues from the US market, whilst AstraZeneca's US sales accounted for 42% of total revenues in the first half of 2026.
Industry consolidation wave
The merger speculation emerged against a backdrop of heightened dealmaking activity across the pharmaceutical sector. Companies announced 16 transactions worth $1 billion or more in the first quarter of 2026 alone, as the industry grapples with an estimated $300 billion in branded pharmaceutical revenue facing patent expiry this decade.
The denial of merger talks appears to have reassured investors that AstraZeneca will continue pursuing its independent growth strategy rather than embarking on a complex integration that many viewed as strategically questionable.
